01/24/2026
Topical Pyrilutamide (KX-826) is potentially a first-in-class medication for the treatment of androgenetic alopecia. It targets testosterone & DHT receptors in the skin & hair follicles (DHT is the hormone involved in the miniaturization process of the hair shaft).
Pyrilutamide (KX-826) is an experimental topical developed by Kintor Pharmaceuticals. It’s in clinical trials in both China and the United States for hair loss.
In 2025, Kintor Pharma states that the long-term safety Phase III clinical trials are complete, and showed excellent safety & efficacy for the treatment of androgenetic alopecia.
The trials show promise, but still require further research before being FDA-approved. Presently; there are only 2 FDA-approved medications for the treatment of androgenetic alopecia (the most common form of hair loss): oral Finasteride (Propecia) & topical Minoxidil (Rogaine).
As Dermatologists (the medical experts for treating hair loss), we’re always looking for better treatments with this hair loss aging process. I believe topical anti-androgens like Pyrilutamide hold significant process in the treatment of androgenetic alopecia.
For more info, visit:
Hairgrowthdoctor.com/pyrilutamide-for-hair-loss